What's Happening?
Patrick Moran, formerly the president of the American Federation of State, County and Municipal Employees (AFSCME) Council 3, has been elected president of AFSCME International, the national arm of the union representing 1.4 million members. Moran, who
previously served as vice president, succeeds Lee Saunders. During his 14-year tenure at Council 3, the Maryland state union tripled its membership, becoming the largest union for state workers in Maryland. Under his leadership, Maryland workers achieved significant raises, new protective laws against extreme heat and workplace violence, and a record-breaking $23 million wage theft settlement. In other Maryland political news, Delegate Bonnie Cullison (D-Montgomery), who did not seek re-election after four terms, has been appointed chair of the Prescription Drug Affordability Board (PDAB). Her appointment, effective August 7, fills the vacancy left by former PDAB chair Van T. Mitchell. Cullison was a key legislative champion for the board's establishment.
Why It's Important?
Moran's elevation to president of AFSCME International signifies a continuation of his aggressive union-building and advocacy strategies on a national scale. His track record in Maryland, marked by substantial membership growth and successful legislative and legal victories for workers, suggests a potential for increased national union influence in labor negotiations, worker protections, and wage disputes. This could impact various sectors, including correctional officers, higher education, and healthcare, by pushing for better working conditions and compensation. For Maryland, Cullison's appointment to lead the Prescription Drug Affordability Board is crucial for the state's efforts to control healthcare costs. As a long-time advocate for the board, her leadership is expected to accelerate its mission to reduce prescription drug costs, initially for those on state health insurance and, with expanded authority in 2025, for all Marylanders. This initiative could serve as a model for other states grappling with rising drug prices, potentially influencing national healthcare policy discussions.
What's Next?
Patrick Moran is expected to focus on continuing to build the AFSCME union nationally, advocating for worker rights, fair wages, and improved working conditions across various public sectors. His leadership will likely involve navigating complex labor relations, potentially including disputes with state administrations, similar to the recent unfair labor practice claims filed against the Moore administration in Maryland. For Delegate Cullison, her immediate task as PDAB chair will be to oversee the board's current mandate to set upper payment limits for specific prescription drugs, such as Jardiance and Ozempic, for state health insurance beneficiaries. Looking ahead to 2025, the board's authority will expand to address prescription drug costs for all Marylanders, requiring Cullison to lead efforts in developing and implementing policies that effectively reduce these costs. This expansion will be a critical test of the board's efficacy and could face challenges from pharmaceutical companies and other stakeholders.
Beyond the Headlines
The transition of Patrick Moran to a national leadership role within AFSCME highlights a broader trend of increasing union activism and influence in the U.S. labor landscape. His success in Maryland, particularly in securing significant gains for state workers, could inspire similar movements and demands for stronger worker protections and benefits nationwide. This shift could lead to more confrontational labor negotiations and a renewed focus on legislative advocacy for labor rights. Concurrently, Delegate Cullison's leadership of the Prescription Drug Affordability Board underscores the growing public and political pressure to address the escalating cost of prescription drugs. The board's efforts in Maryland represent a significant step towards state-level intervention in drug pricing, potentially setting a precedent for other states to adopt similar mechanisms. This could lead to a re-evaluation of pharmaceutical pricing models and increased scrutiny of drug manufacturers, impacting the healthcare industry's economic structure and accessibility of essential medicines.
